|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Such findings suggest that marijuana exposure either recreationally or medicinally may increase the susceptibility to and/or incidence of breast cancer as well as other cancers that do not express cannabinoid receptors and are resistant to Delta9-THC-induced apoptosis.
|
15749859 |
2005 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
For the >10/>10 genotype, there was a significant decrease of P300 amplitude as well as a significant prolongation of P300 latency under pure Δ(9)-THC but not under cannabis extract.
|
21513772 |
2011 |
|
Marijuana Abuse
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Marijuana (hereafter "tetrahydrocannabinol [THC]") use has been associated with liver fibrosis progression in retrospective analyses of patients with chronic hepatitis C (HCV).
|
27225241 |
2016 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our systematic review confirms that placental cannabis pharmacokinetics has been scarcely investigated and that further research is needed to determine advantages and disadvantages for monitoring maternal THC use or the degree of in utero exposure.
|
28645525 |
2017 |
|
Marijuana Abuse
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The cannabinoid receptor 1 (CB<sub>1</sub>) is the principal target of the psychoactive constituent of marijuana, the partial agonist Δ<sup>9</sup>-tetrahydrocannabinol (Δ<sup>9</sup>-THC).
|
28678776 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
A molecularly imprinted polymer (MIP) selective for cannabinoids [Δ<sup>9</sup>-tetrahydrocannabinol (Δ9-THC), 11-nor-9-carboxy-Δ<sup>9</sup>-tetrahydrocannabinol (Δ9-THC-COOH), and 11-hydroxy-Δ<sup>9</sup>-tetrahydrocannabinol (Δ9-THC-OH)] has been synthesized, fully characterized, and applied to the assessment of plasma and urine analysis of marijuana abuse by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS).
|
27815614 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Frequent and occasional cannabis smokers were recruited as participants for four dosing sessions including one active (6.9% Δ<sup>9</sup> -tetrahydrocannabinol, THC) or placebo cannabis-containing brownie, followed by one active or placebo cigarette, or one active or placebo vaporized cannabis dose.
|
27647820 |
2017 |
|
Marijuana Abuse
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
First, we consider the role of human genetic factors and cannabis strain chemotypic differences in contributing to interindividual variation in the response to cannabinoids, such as THC, and review studies demonstrating that THC-induced impairments in decision-making processes are mediated by actions at prefrontal CB<sub>1</sub> receptors.
|
27639448 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vitro studies suggest that synthetic cannabinoids in these preparations are potent agonists at central cannabinoid CB1 receptors (CB1Rs), but few investigations have delineated their cellular effects, particularly in comparison with the psychoactive component of marijuana, Δ<sup>9</sup> -tetrahydrocannabinol (Δ<sup>9</sup> -THC).
|
26732435 |
2017 |
|
Marijuana Abuse
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study is a secondary analysis of the data to examine the abuse liability profile of oral cannabidiol (200, 400, 800mg) in comparison to oral placebo and active smoked marijuana (5.3-5.8% THC).
|
28088032 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also examine potential roles for the hippocampal formation in mediating dysfunctional behavior, and assert that these phenomena reflect disordered physiological activity within the hippocampus and its interactions with other brain regions after exposure to synthetic cannabinoids, and the phytocannabinoids found in marijuana, such as Δ<sup>9</sup>-THC and cannabidiol.
|
28392266 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data demonstrate that abrupt shift changes produce performance, mood, and sleep decrements during night shift work and that smoked marijuana containing low to moderate Δ<sup>9</sup>-THC concentrations can offset some of these effects in frequent marijuana smokers.
|
28728115 |
2017 |
|
Marijuana Abuse
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It contains pictures of marijuana to facilitate the measurement of quantity of marijuana used, as well as questions to assess the use of different forms of cannabis (e.g., concentrates, edibles), methods of administering cannabis (e.g., joints, hand pipes, vaporizers), and typical THC levels.
|
28552942 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, risks and/or benefits associated with the use of unlicensed Δ<sup>9</sup>-THC containing marijuana extracts in pediatric epilepsies remain poorly understood.
|
28190698 |
2017 |
|
Marijuana Abuse
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Benzodiazepines and related drugs were found in 57% of the drug-positive drivers, stimulants in 51%, cannabis (tetrahydrocannabinol, THC) in 34%, and opioids in 18%.
|
28942374 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Parents completed a survey, and urine samples were analyzed for cotinine using LC/MS/MS (limits of detection 0.03 ng/ml) and marijuana metabolites including COOH-THC (limits of detection 0.015 ng/ml).
|
27911435 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Δ<sup>9</sup>-THC and cannabidiol (CBD) are the most abundant phytocannabinoids in Cannabis plants and therapeutic application for both compounds have been suggested.
|
28232276 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Synthetic cannabinoid products have effects that are somewhat similar to those of natural cannabis but more potent and long-lasting than THC.
|
28878698 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Exposure to marijuana advertising among users is common, especially via digital media, and is associated with medical use, heavier use, and use of novel products with higher THC concentrations (i.e., concentrates) or longer intoxication duration (i.e., edibles).
|
28365173 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found THCCOOH (human metabolite of THC) concentrations in 2010 indicating significant consumption of cannabis in all the schools and benzoylecgonine (human metabolite of cocaine) suggesting a limited consumption of cocaine in all but one school.
|
28686986 |
2017 |
|
Marijuana Abuse
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Air samples collected inside cannabis houses showed no detectable THC.
|
28412574 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Disparate findings and reports related to effects of cannabis consumption reflect differential relative concentration of Δ<sup>9</sup>-THC and CBD.
|
28501518 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
A number of elements are responsible for the increased complications of cannabis use, including the increase in the potency of cannabis and an evolution in the ratio between the two primary components, Δ<sup>9</sup>-tetrahydrocannabinol (Δ<sup>9</sup>-THC) and cannabidiol (toward a higher proportion of Δ<sup>9</sup>-THC), Synthetic cannabinoid (SC) use has rapidly progressed over the last few years, primarily among frequent cannabis users, because SCs provide similar psychoactive effects to cannabis.
|
29302228 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consistent 9-THC-content in joints lead to a SJU of 7mg of 9-THC, the integer number closest to the median values shared by both cannabis types.
|
28531767 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subjective and physiological effects, and expired carbon monoxide (CO) were evaluated in frequent and occasional cannabis users following placebo (0.001% Δ<sup>9</sup>-tetrahydrocannabinol [THC]), smoked, vaporized, and oral cannabis (6.9% THC, ∼54mg).
|
28407543 |
2017 |